An International, Randomized, Double-Blind, Controlled Study of Rindopepimut/GM-CSF with Adjuvant Temozolomide in Patients with Newly Diagnosed, Surgically Resected, EGFRvIII-positive Glioblastoma (The "ACT IV" Study)

To confirm that the addition of rindopepimut/GM-CSF to adjuvant temozolomide improves overall survival in patients with newly diagnosed EGFRvIII positive glioblastoma who have undergone gross-total resection.

Neuroscience - Brain Tumor, Neuroscience
Tara Benkers, MD
  • Patients with histologically confirmed, newly diagnosed, de novo glioblastoma.
  • Surgical resection followed by conventional chemoradiation with temozolomide attempted.
  • No history, presence, or suspicion of metastatic disease.
  • No additional treatment for glioblastoma, aside from surgical resection and chemoradiation with temozolomide.
Nathan Hansen and Becky Wood
206-320-3542
206-320-7115